Literature DB >> 25060692

Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.

Lei Hao1, Kyoko Ito1, Kuan-Hsun Huang1, Sudathip Sae-tan2, Joshua D Lambert2, A Catharine Ross3.   

Abstract

OBJECTIVE: Patatin-like phospholipase domain containing 3 (PNPLA3, adiponutrin) has been identified as a modifier of lipid metabolism. To better understand the physiological role of PNPLA3/adiponutrin, we have investigated its regulation in intact mice and human hepatocytes under various nutritional/metabolic conditions. MATERIAL/
METHODS: PNPLA3 gene expression was determined by real-time PCR in liver of C57BL/6 mice after dietary treatments and in HepG2 cells exposed to various nutritional/metabolic stimuli. Intracellular lipid content was determined in HepG2 cells after siRNA-mediated knockdown of PNPLA3.
RESULTS: In vivo, mice fed a high-carbohydrate (HC) liquid diet had elevated hepatic lipid content, and PNPLA3 mRNA and protein expression, compared to chow-fed mice. Elevated expression was completely abrogated by addition of unsaturated lipid emulsion to the HC diet. By contrast, in mice with high-fat diet-induced steatosis, Pnpla3 expression did not differ compared to low-fat fed mice. In HepG2 cells, Pnpla3 expression was reversibly suppressed by glucose depletion and increased by glucose refeeding, but unchanged by addition of insulin and glucagon. Several unsaturated fatty acids each significantly decreased Pnpla3 mRNA, similar to lipid emulsion in vivo. However, Pnpla3 knockdown in HepG2 cells did not alter total lipid content in high glucose- or oleic acid-treated cells.
CONCLUSIONS: Our results provide evidence that PNPLA3 expression is an early signal/signature of carbohydrate-induced lipogenesis, but its expression is not associated with steatosis per se. Under lipogenic conditions due to high-carbohydrate feeding, certain unsaturated fatty acids can effectively suppress both lipogenesis and PNPLA3 expression, both in vivo and in a hepatocyte cell line.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glucose; Lipid emulsion; Nonalcoholic fatty liver disease; Patatin-like phospholipase domain containing 3

Mesh:

Substances:

Year:  2014        PMID: 25060692      PMCID: PMC4175036          DOI: 10.1016/j.metabol.2014.06.016

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  33 in total

1.  Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin.

Authors:  Sharleen M Rae-Whitcombe; Darnell Kennedy; Matt Voyles; Mary P Thompson
Journal:  Biochem Biophys Res Commun       Date:  2010-10-29       Impact factor: 3.575

2.  I148M variant of PNPLA3 confer increased risk for nonalcoholic fatty liver disease not only in European population, but also in Chinese population.

Authors:  Xiaohua Li; Qingchuan Zhao; Kaichun Wu; Daiming Fan
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

Review 3.  Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.

Authors:  Yu-Yuan Li
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

4.  Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis.

Authors:  Aijun Qiao; Jichao Liang; Yaojun Ke; Chenghong Li; Ying Cui; Lian Shen; Huabing Zhang; Anfang Cui; Xiaojun Liu; Changzheng Liu; Yong Chen; Yi Zhu; Youfei Guan; Fude Fang; Yongsheng Chang
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

5.  Lipid emulsion administered intravenously or orally attenuates triglyceride accumulation and expression of inflammatory markers in the liver of nonobese mice fed parenteral nutrition formula.

Authors:  Kyoko Ito; Lei Hao; Amanda E Wray; A Catharine Ross
Journal:  J Nutr       Date:  2013-01-16       Impact factor: 4.798

6.  Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.

Authors:  Manju Kumari; Gabriele Schoiswohl; Chandramohan Chitraju; Margret Paar; Irina Cornaciu; Ashraf Y Rangrez; Nuttaporn Wongsiriroj; Harald M Nagy; Pavlina T Ivanova; Sarah A Scott; Oskar Knittelfelder; Gerald N Rechberger; Ruth Birner-Gruenberger; Sandra Eder; H Alex Brown; Guenter Haemmerle; Monika Oberer; Achim Lass; Erin E Kershaw; Robert Zimmermann; Rudolf Zechner
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

7.  Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome.

Authors:  Mahesh K Basantani; Mitch T Sitnick; Lingzhi Cai; Daniel S Brenner; Noah P Gardner; John Zhong Li; Gabriele Schoiswohl; Kui Yang; Manju Kumari; Richard W Gross; Rudolf Zechner; Erin E Kershaw
Journal:  J Lipid Res       Date:  2010-11-09       Impact factor: 5.922

8.  Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease.

Authors:  Yongcheng Huang; Jonathan C Cohen; Helen H Hobbs
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

9.  Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance.

Authors:  Lu-Ping Ren; Stanley M H Chan; Xiao-Yi Zeng; D Ross Laybutt; Tristan J Iseli; Ruo-Qiong Sun; Edward W Kraegen; Gregory J Cooney; Nigel Turner; Ji-Ming Ye
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

10.  Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.

Authors:  Takahisa Kawaguchi; Yoshio Sumida; Atsushi Umemura; Keitaro Matsuo; Meiko Takahashi; Toshinari Takamura; Kohichiroh Yasui; Toshiji Saibara; Etsuko Hashimoto; Miwa Kawanaka; Sumio Watanabe; Sumio Kawata; Yasuharu Imai; Miki Kokubo; Toshihide Shima; Hyohun Park; Hideo Tanaka; Kazuo Tajima; Ryo Yamada; Fumihiko Matsuda; Takeshi Okanoue
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

View more
  11 in total

1.  Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle.

Authors:  Julia Wattacheril; Kristie L Rose; Salisha Hill; Christian Lanciault; Clark R Murray; Kay Washington; Brandon Williams; Wayne English; Matthew Spann; Ronald Clements; Naji Abumrad; Charles Robb Flynn
Journal:  Hepatol Res       Date:  2017-04-19       Impact factor: 4.288

2.  Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression.

Authors:  Yuying Wang; Zhiqi Lin; Heng Wan; Wen Zhang; Fangzhen Xia; Yi Chen; Xiaoman Chen; Chiyu Wang; Chi Chen; Ningjian Wang; Yingli Lu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

3.  Fibroblast Growth Factor 21 (Fgf21) Gene Expression Is Elevated in the Liver of Mice Fed a High-Carbohydrate Liquid Diet and Attenuated by a Lipid Emulsion but Is Not Upregulated in the Liver of Mice Fed a High-Fat Obesogenic Diet.

Authors:  Lei Hao; Kuan-Hsun Huang; Kyoko Ito; Sudathip Sae-Tan; Joshua D Lambert; A Catharine Ross
Journal:  J Nutr       Date:  2016-01-13       Impact factor: 4.798

4.  Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD.

Authors:  Eduardo Vilar-Gomez; Carlos Jose Pirola; Silvia Sookoian; Laura A Wilson; Patricia Belt; Tiebing Liang; Wanqing Liu; Naga Chalasani
Journal:  Am J Gastroenterol       Date:  2021-05-01       Impact factor: 12.045

Review 5.  How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?

Authors:  Jake P Mann; Robert K Semple; Matthew J Armstrong
Journal:  Front Endocrinol (Lausanne)       Date:  2016-11-16       Impact factor: 5.555

Review 6.  Insights into the Role of PPARβ/δ in NAFLD.

Authors:  Jiapeng Chen; Alexandra Montagner; Nguan Soon Tan; Walter Wahli
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

7.  Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2.

Authors:  Bo Zhou; Steve S Ho; Stephanie U Greer; Noah Spies; John M Bell; Xianglong Zhang; Xiaowei Zhu; Joseph G Arthur; Seunggyu Byeon; Reenal Pattni; Ishan Saha; Yiling Huang; Giltae Song; Dimitri Perrin; Wing H Wong; Hanlee P Ji; Alexej Abyzov; Alexander E Urban
Journal:  Nucleic Acids Res       Date:  2019-05-07       Impact factor: 16.971

8.  Greater liver PNPLA3 protein abundance in vivo and in vitro supports lower triglyceride accumulation in dairy cows.

Authors:  Ryan S Pralle; Sophia J Erb; Henry T Holdorf; Heather M White
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

9.  PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.

Authors:  Gemma Aragonès; Teresa Auguet; Sandra Armengol; Alba Berlanga; Esther Guiu-Jurado; Carmen Aguilar; Salomé Martínez; Fátima Sabench; José Antonio Porras; Maikel Daniel Ruiz; Mercé Hernández; Joan Josep Sirvent; Daniel Del Castillo; Cristóbal Richart
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

10.  The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPKα.

Authors:  Meng Zhang; Yuan Yuan; Qing Wang; Xiaobo Li; Jiuzhang Men; Mingxin Lin
Journal:  Biosci Rep       Date:  2018-11-07       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.